Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease
2014, Janssen under Johnson & Johnson announced the FDA had approved SYLVANT (siltuximab) for the treatment of patients with multicentric Castleman's disease
(MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
(CD) is a non-clonal lymph node hyperplasia and was first described in 1956 by Benjamin Castleman and colleagues.
Other features of Castleman's disease
included the 'onion skin' arrangement of the surrounding lymphocyte (Fig.
Today s approval of a treatment for patients with multicentric Castleman's disease
marks a significant milestone for patients living with this rare disease and underscores the importance of ongoing research and development in areas where there are so few patients with such a high unmet medical need, said Peter L.
Multicentric Castleman's disease
(MCD) is a rare lymphoproliferative disorder.
Generalized lymphadenopathy with morphologic features of Castleman's disease
in an HIV-positive man.
in the retropharyngeal space: CT and MR imaging findings.
Therefore, Kaposi Sarcoma and Multicentric Castleman's Disease
should be considered in the differential diagnosis (8).
Severe polyneuropathy: initial manifestation of Castleman's disease
associated with POEMS syndrome.
arising from the accesory spleen: ultrasonography, computed tomography, and magnetic resonance imaging findings.
THE Blues under-16s development team showed their class defeating a strong Pentyrch, side 35-10 in a charity match for Castleman's disease